
















A thesis submitted in partial fulfillment  
of the requirements for the degree of  










The Faculty of Graduate Studies 
Laurentian University 
Sudbury, Ontario, Canada 
 
© Alexandra Michelle Franklyn, 2016 
 
ii 
THESIS DEFENCE COMMITTEE/COMITÉ DE SOUTENANCE DE THÈSE 
Laurentian Université/Université Laurentienne 
Faculty of Graduate Studies/Faculté des études supérieures 
 
Title of Thesis     
Titre de la thèse   Factors that Impact Opioid Agonist Therapy in Northern and Rural Ontario 
 
Name of Candidate   
Nom du candidat    Franklyn, Alexandra 
       
Degree                            
Diplôme                            Master of Science 
 
Department/Program    Date of Defence 
Département/Programme  Interdisciplinary Health  Date de la soutenance September 06, 2016 
                                                       
APPROVED/APPROUVÉ 
 
Thesis Examiners/Examinateurs de thèse: 
                                                      
Dr. David Marsh  
(Co-Supervisor/Co-Directeur de thèse) 
 
Dr. Joe Eibl  
(Co-Supervisor/Co-Directeur de thèse) 
 
Dr. Nancy Lightfoot    
(Committee member/Membre du comité)    
        
   
      Approved for the Faculty of Graduate Studies 
      Approuvé pour la Faculté des études supérieures 
      Dr. Shelley Watson 
      Madame Shelley Watson 
Dr. Ernst Drucker      Acting Dean, Faculty of Graduate Studies 
(External Examiner/Examinateur externe)   Doyen intérimaire, Faculté des études supérieures 
 
                                                                                                                                  
 
ACCESSIBILITY CLAUSE AND PERMISSION TO USE 
 
I, Alexandra Franklyn, hereby grant to Laurentian University and/or its agents the non-exclusive license to archive 
and make accessible my thesis, dissertation, or project report in whole or in part in all forms of media, now or for the 
duration of my copyright ownership. I retain all other ownership rights to the copyright of the thesis, dissertation or 
project report. I also reserve the right to use in future works (such as articles or books) all or part of this thesis, 
dissertation, or project report. I further agree that permission for copying of this thesis in any manner, in whole or in 
part, for scholarly purposes may be granted by the professor or professors who supervised my thesis work or, in their 
absence, by the Head of the Department in which my thesis work was done. It is understood that any copying or 
publication or use of this thesis or parts thereof for financial gain shall not be allowed without my written 
permission. It is also understood that this copy is being made available in this form by the authority of the copyright 
owner solely for the purpose of private study and research and may not be copied or reproduced except as permitted 






Opioid agonist therapy is the gold standard of care for opioid dependence. 
However, the efficacy of treatment may be hindered by concurrent drug use, including 
cocaine and benzodiazepines. This thesis examines the impact of concurrent drug use on 
treatment retention, and whether it is differentially impacted by geographic region. We 
conducted a retrospective cohort study using electronic medical records from 58 opioid 
agonist therapy clinics in Ontario. One-year treatment retention was the primary outcome 
of interest. Both baseline cocaine and benzodiazepine users experienced decreased 
retention rates than non-users. Patients who used concurrent drugs at higher frequencies 
experienced decreased retention rates compared to those who used less often. Northern 
and urban patients were more likely to be baseline cocaine users, and Southern urban 
patients were more likely to be benzodiazepine users. Both baseline and continued 
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Chapter 1- Geography and Substance Use: Evaluating Factors That Impact 
Opioid Agonist Therapy in the North 
 Opioids are among the most frequently prescribed medications in Canada, and 
prescribing rates continue to rise (Dhalla et al. 2009). Along with the increase in the 
prescribing of opioids, the pattern of opioid use disorders has recently undergone a 
change; heroin use has decreased, and the misuse of prescribed opioids has increased 
(Fischer et al. 2006). The rate of oxycodone prescribing increased by an alarming 850% 
between the years of 1991 and 2007 (Dhalla et al. 2009). In Ontario, the number of 
opioid-related deaths has increased dramatically in recent decades. Between the years of 
1991 and 2010, the rate of opioid-related deaths increased by 242%, with an average age 
of mortality only 42 years of age (Gomes et al. 2014). In one population-based study of 
drug-related deaths in Ontario, nearly 60% were attributed to opioids, with oxycodone 
accounting for a third of all opioid-related deaths (Madadi et al. 2013).  
 The prescription opioid abuse crisis in Northern Ontario communities, including 
First Nations, rural, and remote communities, is especially dire (Kiepek et al. 2012). First 
Nation peoples are an estimated two to five times more likely to die due to overdose than 
the general population (Milloy et al. 2010). In a study of opioid prescribing and opioid-
related death in Ontario, Northern communities experience some of the highest rates 
(Gomes et al. 2011). Over a three year time period from January 2004 to December 2006, 
the Thunder Bay District displayed the highest rate of opioid prescribing (12,635 opioid 
prescriptions dispensed per 1,000 Ontario Public Drug Program eligible) and the second 
highest rate of opioid-related death (9.3 per 100,000 per year), following Manitoulin 
District (11.9 per 100,000 per year).  The Municipality of Sudbury ranked in the top 10 
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for both measures. 
 In this thesis, we discuss methadone and buprenorphine for the treatment of opioid-
dependence and evaluate the factors affecting treatment retention for those patients living 
in Northern, rural, and remote areas living with opioid dependence – including geography 
and concurrent drug use.  
Methadone and Buprenorphine 
 Methadone and buprenorphine are long-acting opioids available for the treatment of 
opioid dependence; this treatment strategy is known as opioid agonist therapy (OAT). 
OAT is a substitution therapy with the goal of harm reduction and improved psychosocial 
functioning (CPSO, 2011). OAT benefits the patient by relieving opioid withdrawal and 
stabilizing psychological, physical, and social functioning (CPSO, 2011), and has been 
shown to reduce mortality rates among opioid dependent populations (Soyka et al. 2011) 
Methadone maintenance therapy (MMT) is considered to be the standard of care 
for patients with opioid-dependence (CPSO, 2011). Methadone is a full opioid receptor 
agonist that is administered orally in liquid form. Methadone dosing is typically observed 
by a pharmacist, nurse, or by a physician to discourage the diversion of the medication. 
By federal regulation, dosing must be witnessed by a regulated health professional. MMT 
not only reduces illicit heroin use, but also reduces the use of other substances – 
including cocaine, amphetamines, and sedatives (Mattick et al. 2014). Studies have also 
found that patients who receive high-dose methadone are less likely to use illicit opiods 
and more likely to be retained in treatment than those patients receiving low-dose 
methadone (Johnson et al. 2000). Another form of OAT is the combination sublingual 
tablet form of buprenorphine and naloxone, which – in Canada – is available as both 
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generic form and under the brand name Suboxone®. Buprenorphine is a partial agonist 
that acts to relieve the patient of their withdrawal symptoms. While having lower 
maximum effect than methadone, the effects of buprenorphine are longer lasting (Mattick 
et al. 2014). Compared to methadone, buprenorphine poses a much lower risk of 
overdose due to it being a partial opioid receptor agonist and being formulated with 
naloxone, an opioid receptor antagonist. However, studies have shown that patients who 
are taking buprenorphine are more likely to continue the use of illicit opioids (Mattick et 
al. 2014) and are at higher risk of dropping out of care (Fischer et al. 1999; Bell et al. 
2006), potentially due to slow induction (Petitjean et al. 2001).  
In Ontario, the availability of OAT has expanded substantially over the past two 
decades. The number of patients initiating OAT in Ontario rose from 6,000 to over 
30,000 between the years of 2000 and 2010 (CAMH, 2011). Currently, there are over 
42,000 patients receiving OAT in the Province of Ontario (CPSO, 2015). With over 50 
clinics across Ontario, the largest network of OAT clinics is the Ontario Addiction 
Treatment Centres (OATC). These clinics are distributed across the province and are 
operated under common management. Although the majority of clinics are concentrated 
in Southern Ontario, there remains a good representation of clinics in Northern areas. 
However, many areas of the province – particularly Northern and rural areas of Ontario – 
are still facing barriers in accessing treatment for opioid dependence. The data presented 
in this thesis is derived from anonymized electronic health records from the OATC clinic 




Impact of Northern and Rural Geography on OAT 
Due to the strict requirement for physician approval (recommendation from the 
provincial licensing body leading to an exemption from the federal narcotics law), 
methadone is often unavailable in rural and remote communities (Kiepek et al. 2012). 
Compared to methadone, buprenorphine has fewer prescribing limitations and prescribing 
physicians do not require special approval (CPSO, 2011). Aside from a lack of 
physicians, people living in rural and remote communities often face additional barriers 
to health care, including having to travel long distances to access pharmacies (Kiepek et 
al. 2012). In a retrospective cohort study on patients initiating MMT in Ontario, more 
than half of patients living in Northern rural areas resided more than 125 km from their 
addiction treatment provider. This was compared to only 16 km for those residing in 
Southern urban communities (Eibl et al. 2015).  
Despite the greater challenges in receiving health care services, it may be the case 
that patients seeking MMT in Northern communities have better treatment outcomes 
(Eibl et al. 2015). In a retrospective cohort study of 48 addiction treatment clinics in 
Ontario, the duration of time that patients were retained in treatment was significantly 
influenced by geographic location; patients residing in Southern urban communities 
remained in treatment for a shorter period of time, while those in Northern rural regions 
experienced enhanced treatment retention (Eibl et al. 2015). Theories as to why this 
pattern exists include: that there is less availability of illicit drugs in these areas, or that 
the patients who overcome the geographic barriers and do access OAT are inherently 
more motivated to be successful in treatment. Both of these theories are further explored 
later in this thesis. 
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Due to the numerous barriers that Northern, rural, and remote communities are 
faced with, patients often rely on alternate forms of health care, including telemedicine. 
Telemedicine – or telehealth – mitigates the barrier that rural and remote communities 
face when accessing medical care. In a retrospective cohort study of OAT clinics in 
Ontario, telemedicine was the primary treatment modality for all clinics that were 
considered Northern rural (Eibl et al. 2016). In a study of over 7,000 patients initiating 
OAT in Ontario, 3,618 patients had received more than 75% of their care via 
telemedicine (Eibl et al. 2016). Of note, these patients experienced retention rates that 
were equal to those patients primarily receiving in-person care (Eibl et al. 2016). Despite 
facing several barriers when accessing health care, patients receiving OAT in Northern 
rural areas appear to benefit from telemedicine, which mitigates the geographic isolation 
often experienced by people who live in these remote communities.  
Benzodiazepines and OAT 
 While OAT has proven a very cost-effective form of treatment, the course of OAT 
may be negatively impacted by concurrent drug use, such as the use of benzodiazepines 
(BZDs) (Brands et al. 2008; Schiff et al. 2007). BZDs are a class of psychoactive drugs 
that are non-opioid central nervous system depressants. The short-term use of BZDs is 
clinically indicated for the treatment of anxiety, acute seizures, and acute alcohol 
withdrawal (Brands et al. 2000). There is currently a lack of evidence for the long-term 
use of BZD (Nielsen et al. 2015). Despite the fact that patients who use BZDs during 
OAT are at increased risk of overdose and death (Brands et al. 2008), BZD use in OAT is 
not uncommon (Bleich et al. 2002; Backmund et al. 2005; Bramness et al. 2007) with as 
many as 37% (Drake et al. 1993) to 66% (Iguchi et al. 1993; Nielsen et al. 2007) of 
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patients in MMT self-reporting concurrent BZD use. In a cross-sectional study of 170 
patients who were receiving OAT, 24.1% met the criteria for BZD dependence, 
according to the Diagnostic Statistical Manual of Mental Disorders-IV (DSM-IV) (Lavie 
et al. 2008).  
 Patients who are receiving OAT and use BZD concurrently are at increased risk of 
overdose and death. In a retrospective study of opioid-related deaths in Ontario, 59.5% 
involved BZDs (Dhalla et al. 2009).  In a nested case-control study of over 43,000 
Ontario patients receiving MMT, concurrent BZD use was independently associated with 
opioid-related death (Leece et al. 2015). Additionally, patients who had received a BZD 
prescription within the past year were twice as likely to suffer from an opioid-related 
death (Leece et al. 2015). Aside from being at greater risk of overdose and death, patients 
who are receiving OAT and use BZDs on an ongoing basis are more likely to continue 
polydrug use – including cocaine and other opioids (Brands et al. 2008). Some studies 
have even found that repeated BZD exposure may modify the metabolism of both 
methadone and buprenorphine (Linterzeris et al. 2006).  
 One of the markers for a positive treatment outcome in OAT is one-year treatment 
retention. Treatment retention has shown to be correlated with a variety of positive health 
outcomes for patients, including reduced rates of drug use, hospitalization, criminal 
activity, and mortality (Peles et al. 2008, Nosyk et al. 2010). While it is known that BZD 
use during treatment is correlated with a more complex clinical course (Brands et al. 
2008; Schiff et al. 2007) and has been shown to impact various patient outcomes 
including unemployment, criminality, and psychological distress (Brands et al. 2008), the 
literature is quite mixed as to whether BZD use impacts one-year treatment retention. 
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Several studies have found that patients who use BZD are at increased risk of premature 
drop-out (Schiff et al. 2007; Peles et al. 2010; Specka et al. 2011), and others have found 
that they are not (Kellogg et al., 2006; Peles et al. 2006; Brands et al. 2008). Several of 
these studies were cross-sectional rather than retrospective or relied on patient self-report 
of BZD use rather than urine toxicology, and few have had a comparable sample size to 
ours. Aside from these factors, the impact of BZD use on patients receiving OAT in 
Northern rural Ontario has not been studied, and is one of the main novelties of this 
thesis. 
 One important caveat is the nature of BZD use, and whether it is prescribed or non-
prescribed. The majority of studies that have examined BZD use in OAT have not 
distinguished between the two. Despite the fact that BZD use in OAT puts patients at 
increased risk of overdose and death, BZD are often prescribed to these patients (Park et 
al. 2015). A retrospective cohort study of over 2,000 patients receiving OAT found that 
40% had received a BZD prescription (Bramness et al. 2007). This number is alarmingly 
high, compared to the 5% of the general age-matched population receiving BZD 
prescriptions (Bramness et al. 2007). However, more than 60% of prescribing was by a 
physician other than the OAT provider. Among the 40% who received a prescription, 
they were more likely to be receiving methadone than suboxone and were more likely to 
be female. When the source of BZD is considered, it appears that non-prescribed BZD 
use is correlated with decreased retention, but prescribed BZD use is not (White et al. 
2014). In fact, the retention rates of those patients using prescribed BZD were nearly 
identical to those patients not using BZD at all. This was compared to those patients 
using non-prescribed BZD, who were more than six times likely to terminate treatment 
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prematurely (White et al. 2014). Therefore, the source of BZD and the nature of its use is 
important to consider when studying treatment retention. However, this is something that 
very few studies have done.  
 In terms of BZD prescribing by region, a retrospective cohort study revealed that 
patients are significantly more likely to have received a prescription for BZDs prior to 
treatment entry if they resided in a Northern rural community (Eibl et al. 2016). More 
research needs to be done to understand these prescribing patterns and whether prescribed 
BZD use impacts treatment retention differentially by geographic location. 
Cocaine and OAT 
 Cocaine is another drug that is commonly used by patients in OAT. One group of 
researchers found that as many as 75% of patients enrolled in MMT experience 
concurrent cocaine use (Grella et al. 1995). This is of great concern given that research 
has shown that cocaine use is predictive of treatment dropout (DeMaria et al. 2000; 
Downey et al. 2000; Hartel et al. 1995; Magura et al. 2002; Brands et al. 2008). Not only 
are non-cocaine users retained in treatment at a higher rate, but these patients successfully 
complete treatment earlier than those patients with baseline cocaine use (Tzilos et al. 
2009). Patients who use cocaine during MMT are also more likely to use heroin (Hartel et 
al. 1995), experience psychological disturbances (Grella et al. 1995), and have a higher 
risk profile for HIV (Grella et al. 1995).  In a secondary analysis of 162 patients receiving 
buprenorphine treatment, both baseline and ongoing cocaine use were found to be 
predictive of poorer treatment outcomes, including opioid use and decreased retention 
rates (Sullivan et al. 2010).  
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Despite the impact of cocaine use on treatment retention being better understood, 
this has not been studied in a Northern rural Ontario context. In a retrospective cohort 
study of patients receiving OAT in Ontario, those that resided in a Northern community 
were more likely to have received a prescription for stimulants prior to treatment entry, 
compared to those patients residing in Southern Ontario (Eibl et al. 2015). Given the 
known complexities regarding concurrent drug use in OAT, it is important that research 
be done to understand the patterns of physician prescribing, especially when these 
substances may be negatively impacting treatment outcomes. Thus, we chose a 
postpositivist lens through which to interpret our results and a transtheoretical model 
through which knowledge translation may occur.   
A Postpositivistic Approach 
In studying the impact of BZD use and cocaine use on OAT retention, a 
postpositivistic approach was used to guide our thinking. Pospostivism is an amended 
version of positivism that is less dualistic. A key assumption of postpositivism is that 
evidence that is established through research is imperfect by nature (Creswell et al. 
2009). This approach holds that our knowledge is shaped by data, evidence, as well as 
rational consideration and that research aims to produce findings that are both factual and 
of relevance in order to help researchers describe a relationship of interest – in this case, 
the relationship between concurrent drug use and treatment retention (Creswell et al. 
2009). In doing so, we will try to remain as objective as possible and reflect on both our 
methods and our findings to identify any bias and to ensure that our conclusions are both 
valid and reliable. 
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The Transtheoretical Model 
 In applying a framework in a clinical context, the transtheoretical model may help 
physicians guide their patients along the stages of change. This model has been used 
previously in addiction research and focuses on what is needed for patients to alter their 
behavior to improve their health (Prochaska et al. 1992). The transtheoretical model 
describes five stages of readiness for change. The first stage is pre-contemplation, where 
the patient does not yet view their behavior as a threat to their health. The second stage is 
contemplation, where the patient is cognizant of their negative health behavior, and 
recognizes it as detrimental to their health. The third stage is preparation, where the 
patient now has intention of changing their behavior within the next month. The fourth 
stage is action, where the patient has made specific changes to improve their lifestyle, but 
these changes have been for six months or less. Lastly is the maintenance stage, where 
the patient has abstained from the negative health behaviour for at least six months 
(Prochaska et al. 1992). In our research, the negative health behavior refers to concurrent 
drug use, whether the use of BZD or cocaine while receiving OAT. The belief is that the 
extent to which a patient is ready for change may predict their likelihood of concurrent 
drug use, and therefore their likelihood of treatment retention. Despite patients in OAT 
being in the action stage with regards to their opioid use, they may be at an earlier stage 
with regards to their concurrent drug use. If this is the case, physicians should help tailor 
treatment to build motivation for patients to change their negative health behavior, 
whether it be the use of cocaine or BZD. 
We will also be discussing the role of contingency management in OAT, which is 
one of the ten processes of change in the transtheoretical model. The concept behind 
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contingency management is that the physician provides a reward for positive behavior 
and punishment for negative behavior (Glanz et al. 2008). In OAT, take-home doses 
(known as carries) are often achieved as a result of contingency management, whereby 
abstaining from concurrent drug use will earn the patient carries (Brands et al. 2002). 
Overall, the transtheoretical model may help researchers better understand why patients 
use concurrent drugs and allow a better understanding of the steps that can be taken to 
increase patients’ readiness for change and, therefore, increase treatment retention.  
Hypothesis 
Based on previous research, we expect that both baseline and ongoing BZD or 
cocaine use will negatively impact treatment retention, and that with an increasing 
prevalence of BZD or cocaine use, there will be a decrease in treatment retention. 
Furthermore, there will be differences in the extent to which concurrent drug use impacts 
OAT outcomes based on geographic location. 
Summary 
Currently, there exist several knowledge gaps with respect to addiction treatment 
in the North. Further research must be conducted to better understand the unique 
implications of opioid dependence in the North, such as: how Northern Ontario patients 
seeking OAT are impacted by their geographic location, what method of treatment 
delivery provides the most efficacious form of care, and how Northern Ontario patients 
receiving OAT are impacted by concurrent drug use in order to provide the highest 
quality of care to this unique and vulnerable population. Understanding nuances of the 
rural and remote geography of Northern Ontario may aid planners and policy makers to 
enhance care for patients living in these geographically isolated regions. In this thesis, we 
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explore how concurrent drug use uniquely impacts treatment retention for patients living 
in Northern and rural regions of the province, as well as make recommendations as to 
how we should proceed to enhance care for this patient population. 
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Chapter 2: The Impact of Cocaine Use on Treatment Retention 
 
Opioids are a family of semi-synthetic molecules having a pharmacologically 
similar effect to morphine (derived from opium), a naturally existing pain reliever. 
Opioids are among some of the most commonly prescribed medications in Canada, and 
prescribing rates continue to rise (Dhalla et al. 2009). Opioids have a high incidence of 
dependence, with approximately 200,000 Canadians dependent on prescription opioids 
(Webster et al. 2012). Specifically in Ontario, prescription opioid related deaths increased 
by 242% between the years of 1991 and 2010 (Gomes et al. 2014).   
For those who become opioid dependent, there is a treatment known as opioid 
agonist therapy (OAT), a maintenance therapy whereby the patient is relieved of their 
opioid withdrawal by taking either methadone or buprenorphine, and is able to return to 
normal social, psychological, and physical functioning. Patients in OAT experience better 
treatment outcomes when they are retained in treatment for at least one year, and there is 
considerable evidence to support that one year retention is strongly correlated with a 
variety of positive health outcomes including: reduced rates of drug use, relapse, 
hospitalization, mortality, and illegal activity (Peles et al. 2008; Nosyk et al. 2010). There 
are currently over 42,000 patients receiving OAT in Ontario (CPSO, 2015). 
 In remote communities, such as those in Northern Ontario, the opioid crisis is 
particularly rampant (Kiepek et al. 2012). These Northern communities experience some 
of the highest rates of opioid prescribing and opioid related death in the province (Gomes 
et al. 2011). Due to the vast geography of the North, these communities often face 
barriers when accessing various forms of health care, often relying on technology such as 
telemedicine to receive treatment (Eibl et al. 2016). Given the additional barriers that 
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Northern patients face, it is of great importance that OAT outcomes and factors relating 
to its success and failure be studied in this geographic context, to better understand how 
treatment can be tailored for these patients.  
Although OAT has been shown to be a very cost effective form of treatment, its 
efficacy may be negatively impacted by concurrent drug use, including the use of 
cocaine. Cocaine is a stimulant that alters the brain’s ability to regulate dopamine. By 
inhibiting dopamine reuptake, cocaine causes a dopamine accumulation at the synapse 
(NIDA, 2010). This increase in dopamine is typically associated with a temporary 
increase in energy, alertness, and mood (Boys et al. 2001). While cocaine use has been 
shown to increase cognitive function immediately after use, sustained long-term use 
appears to impair cognitive function (Spronk et al. 2013). Currently, there is no 
pharmacological treatment for cocaine dependence (Tzilos et al. 2009; Dutra et al. 2008), 
and current guidelines are limited to the use of cognitive behavioral therapy (CBT) and 
contingency management (Rawson et al. 2002; Epstein et al. 2003; Tzilos et al. 2009). 
However, research surrounding the efficacy of CBT and contingency management for 
cocaine dependence in OAT is inconclusive (Tzilos et al. 2009; Penberthy et al. 2010; 
Darker et al. 2012). 
Studies have found that cocaine use is quite common in patients in OAT, with as 
many as 30-50% of patients self-reporting cocaine use at treatment initiation (Raffa et al. 
2007; Cone et al. 2012; Roux et al. 2016). The prevalence of cocaine use in OAT is of 
great concern given that studies have found regular cocaine use to be predictive of poorer 
treatment outcomes. Specifically, cocaine-using patients tend to suffer from 
psychological distress (Roux et al. 2016), require higher doses of methadone to stabilize 
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(Maremanni et al. 2000), have a higher risk profile for HIV (Grella et al. 1995), are more 
likely to use heroin (Hartel et al. 1995), and are at increased risk of treatment drop-out 
(Brands et al. 2008; Salamina et al. 2010; Sullivan et al. 2010; Proctor et al. 2015). 
Additionally, a retrospective cohort study in the U.S. found that patients who regularly 
use cocaine while on OAT are at increased risk of overdose, with as many as one third of 
opioid related deaths involving cocaine (Visconti et al. 2015). 
 Given the greater clinical complexity of OAT patients who engage in cocaine use, 
it is of great importance to study this population in the context of Northern and rural 
settings, where patients are already faced with an abundance of barriers when accessing 
care.  In this study, we investigate the impact of geography on cocaine use and treatment 




In Ontario, OAT is regulated by formal treatment guidelines established by the 
College and Physicians of Ontario (CPSO), which set out expectations with respect to 
physician practice and are enforced through peer-audits (CPSO 2011). These guidelines 
are in addition to the federal requirement for an exemption to prescribe methadone. 
Variability of practice within the guidelines is possible, but is generally limited. This 
study is based on the electronic medical records of patients treated within the Ontario 
Addiction Treatment Centres (OATC), a network of over 50 OAT clinics across the 
province operated under common management. Standardized evidence-based best 
practice policies and operating procedures are in place within the clinic network, which 
further limit the likelihood of variability of treatment between sites and between 
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physicians. To maintain consistency, patients are typically seen by the same physician 
throughout the course of their treatment.  
Cohort Definition:  
We conducted a retrospective cohort study of patients initiating OAT within 
OATC for the first time between January 1st, 2011 and June 17th, 2012 in the Province of 
Ontario. We defined first time OAT as no previous history of methadone or 
buprenorphine use in the OATC network, based on review of records dating back to 
1999. Patients were started on either methadone or suboxone (the only two medications 
approved for this purpose in Canada at the time of the study) and were allowed to 
transition between these medications over the course of treatment. Patients were at least 
15 years or older (patients < 18 years of age accounted for < 1% of cohort), and were 
residents of Ontario. All patients were followed from the date of OAT initiation to the 
date of medication discontinuation, or end of the study period (June 2013). Drug 
discontinuation was defined as a patient not receiving a dose of methadone or 
buprenorphine for 30 consecutive days.  
Data Sources 
The dataset used for this study was derived from anonymized electronic medical 
records from the OATC network of 58 addiction treatment centers across the Province of 
Ontario. Methadone prescribing, treatment delivery, and data management are 
harmonized across the clinic network. Prior to data analysis, personal identifiers were 
replaced with an encrypted unique identifier. Cluster analysis (testing relation between 
individual clinic and treatment retention) did not reveal any significant differences among 
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clinics with respect to increased/decreased treatment retention by individual clinic or 
physician.  
Cocaine Use 
Patients were categorized by baseline and ongoing cocaine use based on urine 
toxicology screening. Urine toxicology screening has the ability to detect 
benzoylecgonine – a metabolite of cocaine (Handford et al. 2011). Screening is 
performed on all patients one to two times per week throughout the treatment episode via 
an enzyme immunoassay, which has the ability to detect benzoylecgonine in the urine for 
3 to 5 days (Handford et al. 2011). Patients were considered to be baseline cocaine users 
if they had any cocaine positive urine samples in their first month of treatment. Patients 
were also stratified into one of four groups depending on the frequency of cocaine 
positive urine samples throughout treatment. 
Definition of Treatment Retention 
Patients were followed from treatment initiation for at least one year, to a 
maximum follow-up date of June 17th, 2013. For the purpose of this study, treatment 
retention has been defined as being in treatment for one year of continuous and 
uninterrupted OAT, based on having received a prescription refill (for methadone or 
buprenorphine) within 30 days of the previous prescription end date (i.e. no period of 30 
consecutive days without a dose of medication). One year treatment retention was chosen 
as the primary outcome of interest due to its correlation with positive health outcomes for 
patients (Peles et al. 2008; Nosyk et al. 2010). 
In the event that a patient transitioned to a non-OATC clinic, was incarcerated, 
hospitalized, or was otherwise prevented from refilling their prescription for 30 
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consecutive days while still receiving treatment elsewhere, it is possible for type 1 error 
to occur (i.e. for the patient to be classified as having ended treatment despite continuing 
to be in care). 
Statistical Analysis 
Descriptive statistics were summarized for baseline characteristics of patients, and 
standardized differences were used to compare patient groups. Baseline characteristics 
included: percentage of patients that were male/female, Northern/Southern, and 
rural/urban, median age, median peak methadone dose, median days retained, the 
percentage of cocaine positive urine samples, and the one-year retention rate. For the 
purpose of this study, only a patient’s first-treatment episode was considered. For the 
primary analysis, a Cox proportional hazard analysis was used to characterize the time to 
treatment discontinuation between the cocaine positive and negative patient groups with 
adjustment for the impact of age, gender, northern and rural location. Cox Proportional 
analysis and log-rank test were performed using SPSS 24.  
Results: 
Patient Demographics  
Our cohort consisted of 3,835 patients across 58 clinics. The median age was 
31.45 years and 59% of the cohort was male. 37% of the population resided in Northern 
Ontario  (where 20 of the 58 clinics were located) and only 16% resided in a rural 
community. Patients residing in Northern Ontario were 41.2% less likely to drop out of 
treatment by the one-year mark, and males were 28.8% more likely to drop out than 
female patients. Transgendered patients were classified with their chosen gender identity 
group by the clinical team and therefore, a more nuanced analysis of gender is not 
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possible in this data set. There were no significant differences in treatment retention for 
patients living in rural or urban centres.  
Baseline Cocaine Use 
The cohort was stratified based on cocaine use at treatment initiation and 
throughout treatment. Of the 3,835 patients, 2,528 (65.9%) did not have cocaine positive 
urine samples in their first month of treatment, and 1,307 patients (34.1%) did. There 
were no gender differences (p=0.692) between the two groups, with both groups having 
approximately 59% male and 41% female patients. Patients were 49.5% less likely to 
have a cocaine positive urine sample in their first month of treatment if they lived in a 
rural area and were 24.3% more likely to have a cocaine positive urine sample in their 
first month of treatment if they lived in the North. First month cocaine users had an 
increased median peak dose of methadone (80 mg vs 75 mg), and had a lower median 
retention of 212 days, compared to 302 days.  
Retention and Baseline Cocaine Use 
 Once patients were categorized by first month cocaine use, a Cox proportional 
analysis was performed to examine the proportion of patients retained in treatment for 
one year. The variables included in the analysis were: age [aHR= 0.98 (95% CI 0.98 – 
0.98)], gender (female [aHR= 0.78 (95% CI 0.71 – 0.85)]), geography (North [aHR= 0.59 
(95% CI 0.53 – 0.65)] and rural [aHR= 0.99 (95% CI 0.87 – 1.13)], and first-month 
cocaine use [aHR= 1.12 (95% CI 1.03 – 1.23)]. Of those patients who did not have 
cocaine positive urine samples in their first month of treatment, 46% were retained at one 
year. This was compared to 39% for patients who were positive at baseline. Of non-users 
who were retained for one year, 89% were cocaine negative at one-year follow up. Of the 
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1,307 patients who had cocaine positive urines on admission, 508 remained in care at the 
one-year mark, 55% of which were cocaine negative. Lastly, patients were 12.4% more 
likely to not be retained in treatment if they had cocaine positive urine samples in their 
first month of treatment. 
Proportion of Cocaine Positive Urine Samples 
Patients were also categorized by the proportion of cocaine positive urine samples 
throughout treatment, separated into four groups (0-25%, 25-50%, 50-75% and 75-100% 
positive). Of the 3,835 patients, 2,941 had cocaine positive urine samples less than 25% 
of the time, and 48% of these patients were retained in treatment for one year.  We found 
333 patients had cocaine positive urine samples between 25-50% of the time – 37% of 
these patients were retained in treatment for one year. 207 patients had cocaine positive 
urine samples 50-75% of the time, and they experienced a retention rate of 33%. 
Compared to patients with < 25% of urines cocaine positive, these patients were 31.3% 
more likely to not be retained in treatment. 356 patients had cocaine positive urine 
samples more than 75% of the time, and they were retained at a rate of 22%. These 
patients were 96.5% more likely to not be retained, compared to the <25% group. 
Cocaine Use and Geography 
 Patients were also stratified by location of residence. Patients were considered 
residents of Northern Ontario or Southern Ontario, as defined by the Local Health 
Integration Network (LHIN). If patients lived in LHIN 13 or 14, they were considered 
residents of Northern Ontario. For the four cocaine use groups listed above, the retention 
rates in the North were: 59%, 44%, 37%, and 31%, respectively. In Southern Ontario, 
retention rates were: 40%, 32%, 31%, and 19%, respectively. Despite having the same 
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frequency of cocaine positive urine samples, patients in Northern Ontario were 40.3% 
less likely to terminate treatment than were Southern patients. 
Discussion:  
Previous studies have concluded that cocaine use in OAT is predictive of a more 
complex clinical course, of poorer treatment outcomes, and lower retention rates (Raffa et 
al. 2007; Cone et al. 2012; Roux et al. 2016). Our results corroborate current findings in 
the literature that cocaine use is common among patients seeking OAT and that baseline 
cocaine use is predictive of decreased retention rates (Brands et al. 2008; Proctor et al. 
2015). Given that cocaine use has been found to be predictive of treatment dropout, it is 
important to identify predictors of cocaine use in OAT. In our cohort, there were no 
significant differences in gender or age with respect to cocaine use. We did, however, 
find that geography was correlated with cocaine use. Patients who were from the North 
were more likely to use cocaine in their first month of treatment, as were patients living 
in urban areas. This may be due to the availability of cocaine, either in terms of cost of 
drug or its accessibility.  
Studies have found that both baseline cocaine use and cocaine use throughout 
treatment are predictive of premature dropout (DeMaria et al. 2000; Downey et al. 2000; 
Hartel et al. 1995; Magura et al. 2002; Brands et al. 2008). In our study, patients who 
were not using cocaine at treatment initiation (those who had no cocaine positive urine 
samples during their first month of treatment) benefited from increased retention rates. 
Those patients who did have cocaine positive urine samples in their first month of 
treatment were 12.4% more likely to terminate treatment by the one-year mark than those 
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patients who were initially cocaine negative. This is not surprising given that cocaine use 
is a marker for greater clinical complexity, including premature dropout.  
In this study, we examined one-year treatment retention for various frequencies of 
cocaine use. Patients were categorized by the percentage of cocaine positive urine 
samples throughout treatment duration: 0-25%, 25-50%, 50-75%, and 75-100%.  We 
found that as frequency of cocaine use increases, the likelihood of treatment retention 
decreases. Roughly 48% of patients who had cocaine positive urine samples 0-25% of the 
time were retained in treatment for one full year and approximately 37% of patients who 
used 25-50% of the time were retained in treatment for one year. This number was lower 
for patients who had used 50-75% of the time (33%) and even lower for those patients 
who had used most often (22%). Patients who had 75% of more of their urines cocaine 
positive were nearly twice as likely to dropout of treatment. These findings support our 
hypothesis that cocaine use is correlated with treatment dropout, and that the more 
frequently a patients uses, the more likely they are to terminate treatment prematurely.  
Once patients had been stratified by baseline cocaine use, they were also 
compared in terms of ongoing cocaine use throughout treatment. Of those patients who 
were negative on admission, 89% were cocaine negative at the 1-year mark. While this 
number is fairly high, this suggests that 11% of initial non-users either had a rate of 
cocaine use of less than once per month prior to OAT treatment entry or began using 
cocaine during treatment. Thus, it may be the case that patients have given up their opiate 
of choice, but have replaced it with another drug such as cocaine, but this is unusual. The 
vast majority of non-users remain non-users throughout the course of treatment. Of the 
patients who were cocaine positive on admission, more than half (55%) of those who 
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remained in treatment were cocaine negative at the 1-year mark. Given that OAT does 
not specifically treat cocaine dependence in a pharmacological sense, this may seem 
surprising. However, in both the Northern and Southern population, the percentage of 
patients with cocaine positive urine samples declined over the course of treatment for 
those patients who were retained. This is likely a result of contingency management 
whereby patients are motivated to abstain from cocaine use in order to obtain carried (i.e. 
take home) doses. Contingency management has been shown to reduce cocaine use in 
patients who are receiving methadone (Rawson et al. 2002). This decrease may also be a 
result of patients abstaining from illicit opioid use and making a change in lifestyle that 
reduced their contact with drug users or suppliers. Finally, there is some evidence from 
animal studies suggesting higher doses of methadone may reduce cocaine – as well as 
opioid – use (Leri et al., 2004).  
In studying the impact of cocaine use on treatment retention, we focused on the 
relationship between cocaine use and retention in a Northern Ontario context. Due to the 
vast geographic landscape, Northern Ontario communities are often isolated from large 
urban centres. Because of this, these remote communities often face several barriers when 
accessing health care, especially when seeking OAT. A retrospective cohort study of 
patients seeking OAT in Northern Ontario found that more than half of patients residing 
in Northern rural communities lived 127 km or more from their addiction care provider, 
compared to only 16 km for their Southern urban counterparts (Eibl et al. 2015). 
Interestingly, this study also demonstrated that patients living in Northern areas were 
more likely to be retained in treatment than their Southern counterparts. While this may 
seem somewhat surprising given the barriers that Northern patients face, it may be that 
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these patients are more motivated to continue with treatment given the known difficulties 
in seeking OAT. Patients who have OAT at their disposal in Southern urban centers may 
not be as motivated to complete treatment, given that they could easily re-enter treatment 
if they dropout. It is clear from this study that the increased treatment retention in the 
North is not the result of lower prevalence of cocaine use in the North (in fact, Northern 
patients had a higher prevalence of cocaine use than Southern patients). 
Until recently, it was thought that substance misuse was more prevalent in urban 
areas compared to rural (Lambert et al. 2008). However, studies have found that 
substance use is an issue of great relevance to people living in rural areas, with cocaine 
use being no exception. One study that relied on longitudinal survey information found 
that youth aged 12-17 living in rural areas experience increased rates of cocaine use 
compared to urban youth (Lambert et al. 2008). However, our results suggest that cocaine 
use is more common in the urban populations in Ontario. Our findings also indicate that 
patients who were cocaine negative on admission were more likely to live in a rural area, 
and were more likely to live in the South. These contrasting findings may be explained by 
differing types of data collection (self-reported cocaine use vs. urinalysis), different 
geographic contexts (Canada vs. US), or by different age distribution (youth vs. general 
population). 
In using a postpositivistic approach, we have reflected on both our methods and 
our findings to identify any bias and limitations of our research. Firstly, if a patient 
terminated treatment, we were unable to determine the reason. It is possible that they 
simply terminated treatment, that they sought treatment through a non-OATC clinic, had 
an extended hospitalization or incarceration, or died. Secondly, due to the nature of a 
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retrospective cohort, we were unable to determine certain patient details, such as a 
patient’s cocaine use history or the amount of cocaine used. Additionally, it is possible 
that the proportion of cocaine positive urine samples was misrepresented by patients who 
initiated treatment, dropped off one urine sample, then left treatment. Another limitation 
is that this study only focuses on one network of clinics offering OAT. The clinic 
network studied comprises approximately one third of the patients receiving OAT in 
Ontario. Therefore, there is the possibility of selection bias and that the findings within 
this clinic network may not generalize to other treatment settings in the Province. 
However, this can also be seen as a strength of the study, given that the standardized 
treatment in this clinic network adds integrity to the comparisons. 
This study has many other strengths, one of which being the large sample size. 
With over 3,800 patients in the dataset, the study captures a considerable portion of 
patients receiving OAT in Ontario. The nature of data collection is another strength of 
this study. Previous studies looking at cocaine use by geographic region have been 
dependent on patient self-report, which is often unreliable. Although there is potential for 
error with urine toxicology, this method better captures true patterns of cocaine use 
amongst patients, particularly given the high frequency of urine testing in this sample 
(once to twice weekly). Lastly, while studies have been conducted on the impact of 
cocaine use in OAT, the remote Northern Ontario context has not been studied.  
The findings of our study support the idea that cocaine use in OAT is predictive 
of poorer treatment outcomes, and that this is differentially affected by geographic 
region. Even with similar patterns of cocaine use, patients living in the North appear to 
benefit from greater retention rates. Knowing that cocaine use is a marker for greater 
	 26	
clinical complexity and decreased retention rates, it is important that physicians know the 
predictors of cocaine use and how to access specialized or enhanced treatment for the 
cocaine-using population.  
Table 1. Characteristics of baseline cocaine users and non-users. Descriptive statistics were summarized for baseline 
characteristics of patients, and standardized differences were used to compare patient groups. Patients were considered baseline 
cocaine users if they had any cocaine positive urine samples in the first month of treatment 
 Initially Negative (n = 2528, 65.9%) Initially Positive (n = 1307, 34.1%) 
Male / Female 1508 (59.7%) / 1020 (40.3%) 771 (59.0%) / 536 (41.0%) 
North / South 906 (35.8%) / 1622 (64.2%) 496 (38.0%) / 810 (62.0%) 
Urban / Rural 2076 (82.1%) / 452 (17.9%) 1163 (89.1%) / 143 (10.9%) 
Median Age (Q1, Q3; SD) 31.7 (25.8, 40.8; SD=10.8) 30.7 (25.4, 39.1; SD=9.6) 
Median Peak Methadone Dose (Q1, Q3; 
SD) 
75 (50, 100; SD=34) 80 (60, 105; SD=33) 
Median Peak Suboxone Dose ( Q1, Q3; SD) 10 (8, 16; SD=7) 8 (8, 16; SD=7) 
Median Days Retained (Q1, Q3; SD) 302 (53, 545; SD=277) 212 (62, 501; SD=260) 
Median Percent Positive Results (Q1, Q3; 
SD) 
0.0 (0.0, 1.3; SD=9.7) 34.4 (13.9, 76.7; SD=33.8) 
Percent Positive 
Results 
[0, 25) 2432 (96.2%) 507 (38.8%) 
[25, 50) 68 (2.7%) 265 (20.3%) 
[50, 75) 19 (0.8%) 188 (14.4%) 
[75, 100] 9 (0.4%) 347 (26.5%) 
At Month 3 
Day 60 to 90 
Positive / Negative 207 (11.2%) / 1640 (88.8%) 635 (65.1%) / 340 (34.9%) 
Retained 1847 (73.1%) 975 (74.6%) 
At Month 6 
Day 150 to 180 
Positive / Negative 218 (14.4%) / 1291 (85.6%) 444 (58.3%) / 317 (41.7%) 
Retained 1509 (59.7%) 716 (58.2%) 
At Month 9 
Day 240 to 270 
Positive / Negative 164 (12.3%) / 1172 (87.7%) 315 (51.0%) / 303 (49.0%) 
Retained 1336 (52.8%) 618 (47.3%) 
At Month 12 
Day 330 to 360 
Positive / Negative 135 (11.1%) / 1077 (88.9%) 246 (45.4%) / 296 (54.6%) 
Retained 1212 (47.9%) 542 (41.5%) 
Retained / Not-Retained 365 Days 1163 (46.0%) / 1365 (54.0%) 508 (38.9%) / 799 (61.1%) 
	 28	
Figure 1.1 - Treatment retention by baseline cocaine use. A Cox proportional hazard analysis was used to characterize the time to 
treatment discontinuation between the patient groups. Log-rank comparison of these curves yielded a Chi-Square value of 8.975 with a 
significant p value of 0.0027. Baseline cocaine users were 12% more likely to drop out of treatment than baseline non-users 
[aHR=1.124 (95% CI 1.03 –1.23)]. 
 


















Figure 1.2 - Treatment retention by proportion of cocaine positive urine samples. A Cox proportional hazard analysis was used to 
characterize the time to treatment discontinuation across the four patient groups. Log-rank comparison of these curves yielded a Chi-
Square value of 114.3 with a significant p-value of <0.0001. Patients with 50-75% of urines cocaine positive were 31% more likely to 
drop out of treatment than patients in the 0-25% reference group [aHR=1.313 (95% CI 1.10 –1.56)]. Patients with 75-100% of urines 
cocaine positive were 96.5% more likely to drop out of treatment than patients in the 0-25% reference group [aHR=1.97(95% CI 1.73 
–2.24)]. 



















Figure 1.3 - Proportion of patients retained in treatment for one year, by frequency 
of cocaine use, comparing North vs. South. When considering similar proportions of 
cocaine positive urine samples, Northern patients benefit from increased retention rates 
compared to their Southern counterparts. Cross tabulations were performed. A significant 
association was found for the first (0-25%) group (Chi-Squared value = 105.7, p = 
0.000), the second (25-50%) group (Chi-Square value = 4.37, p = 0.037), and the fourth 
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Chapter 3: The Impact of Benzodiazepine Use on Treatment Retention 
 Opioids are one of the most frequently prescribed medications in Canada, and the 
misuse of prescription opioids is becoming increasingly more prevalent (Dhalla et al., 
2009). In Ontario, the number of opioid-related deaths increased by an alarming 242% 
between 1991 and 2010 (Gomes et al. 2014). This problem is particularly severe in 
Northern Ontario, which is home to the highest rates of both opioid prescribing and 
opioid-related death within the province (Gomes et al. 2011). 
 In a retrospective study on opioid-related deaths in Ontario, 59.5% of deaths 
involved BZD, a non-opioid central nervous system depressant (Dhalla et al., 2009). The 
short-term use of BZD is clinically indicated in patients who suffer from anxiety, 
seizures, or acute alcohol withdrawal. BZD are considered to be high risk for dependence 
(Nutt et al., 2001), especially when used long-term (Fang et al., 2009). Long-term BZD 
dependence can cause serious harm including impaired sleep, decreased mood, and a 
decline in cognitive function (Lintzeris et al. 2010). 
 BZD are often prescribed to patients who are on opioid agonist therapy (OAT) 
(Park et al., 2014). In a cross sectional survey of patients in OAT, two thirds of patients 
reported concurrent BZD use (Nielsen et al., 2007). Another cross-sectional study of 170 
OAT patients found that 24% of patients met the criteria for BZD dependence, according 
to the diagnostic statistical manual of mental disorders-IV (DSM-IV) (Lavie, et al., 
2009). The use of BZD during OAT puts patients at an increased risk for overdose and 
death (Brands et al., 2008). A review of methadone fatalities that involved other drugs 
found that BZD were detected in 59% of deaths (Mikolaenko et al. 2002). Additionally, 
patients who are prescribed methadone and use BZD on an ongoing basis are more likely 
		 32	
to continue polydrug use, including cocaine and other opioids (Brands et al., 2008). 
While previous studies reveal mixed findings about whether ongoing BZD use negatively 
affects treatment retention, BZD use during treatment has been correlated with a more 
complex clinical course (Kellogg et al., 2006; Schiff et al., 2007; Brands et al., 2008). 
Additionally, BZD misuse is correlated with negative patient outcomes such as 
unemployment, involvement in criminal activity, and psychological distress (Brands et 
al., 2008).  
A review of the literature reveals that most BZD prescribing is in agreement with 
clinical guidelines, however, there does exist some prescribing that is contrary to clinical 
guidelines (Adamson et al., 2012). A questionnaire answered by 66 internationally 
recognized experts on pharmacotherapy suggested that the risks of BZD are over stated 
and revealed support of long-term BZD use (Uhlenhuth et al., 1999), despite the lack of 
evidence for effectiveness of long-term BZD use (Nielsen et al. 2015). A qualitative 
study of 35 general practitioners revealed that physicians are often cautious when 
initiating BZD use in their patients, however, they view the prescribing of BZD as “the 
lesser evil” compared to the patient’s psychosocial problems (Anthierens et al., 2007).  
 Along with concurrent drug use, geography is another important factor when 
studying OAT retention rates. In this study, we focus on differences in BZD use and 
retention between Northern and Southern Ontario, as well as rural and urban Ontario. An 
important difference between the North and South is the population density. Northern 
Ontario has approximately 10% of the population in about 90% of the geographic area. It 
is for this reason that patients often have to travel large distances to access OAT services 
and pharmacies to dispense their medication (Eibl et al. 2015). Despite facing a variety of 
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barriers when accessing care, patients in the North experience increased treatment 
retention rates (Eibl et al. 2015). Further research must be done to better understand why 
this occurs, including whether patterns of current drug use, such as BZD, plays a role.  
While the potential risks of BZD use during OAT are clear, it is not yet clear 
whether abstaining from BZD during OAT is beneficial for patients who suffer from co-
occurring mental health disorders, where BZD may be clinically indicated. In this study, 
we evaluate treatment retention for patients using BZD and those who do not; further, we 
also evaluate whether this is differentially impacted by geographic location. 
Methods: 
Cohort Definition:  
We conducted a retrospective cohort study of patients initiating OAT for the first 
time between January 1st, 2011 and June 17th, 2012 in the Province of Ontario. We 
defined first time OAT as no previous history of methadone or buprenorphine use in the 
network of clinics studied, based on review of records dating back to 1999. Patients 
started on either methadone or suboxone, which were the only medications approved for 
opioid dependence in Canada at the time of the study. Patients were allowed to transition 
between these two medications over the course of treatment.  Patients were at least 15 
years or older (patients < 18 years of age accounted for < 1% of cohort), and were 
residents of Ontario. All patients were followed from their date of OAT initiation to the 
date of drug discontinuation (patient did not receive a methadone or buprenorphine dose 





The dataset used for this study was derived from anonymized electronic medical 
records from a group of 58 addiction treatment centers across the Province of Ontario – 
the Ontario Addiction Treatment Centers (OATC). Prior to data analysis, personal 
identifiers were replaced with an encrypted unique identifier.  
BZD Use 
Patients were categorized by baseline BZD use (defined as having any BZD 
positive urine samples in their first month of treatment) and by ongoing BZD use 
(determined by the proportion of BZD positive urine samples throughout treatment). 
Urine toxicology screening was performed one to two times per week on all patients 
throughout their time in care via an enzyme immunoassay, which has the ability to detect 
BZD in the urine (Handford et al. 2011). However, this test is unable to differentiate 
between different BZD, which include, but are not limited to:  diazepam, clonazepam, 
and lorazepam. The majority of urine toxicology screens reported were conducted using 
an antibody reactive to diazepam (and related compounds). Therefore, the use of 
clonazepam may be underestimated. The detection period and sensitivity differs for each 
BZD, ranging from a few hours to a few days (Handford et al. 2011). 
Definition of Treatment Retention 
Unless treatment was terminated, all patients were followed for at least one year 
to a maximum follow-up date of June 17th, 2013. Continuous OAT was assessed on the 
basis of not having a period of 30 or more consecutive days without a dose of medication. 
We defined a patient as having been retained in treatment if they completed at least one 
year of continuous and uninterrupted OAT. In the event that a patient transitioned to a 
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non-OATC clinic, was incarcerated, hospitalized, or was otherwise prevented from 
refilling their prescription, it is possible for type 1 error to occur. 
Statistical Analysis 
Descriptive statistics were summarized for baseline characteristics of patients, and 
standardized differences were used to compare patients in the various BZD use groups. 
Baseline characteristics included: percentage of patients that were male/female, 
Northern/Southern, and rural/urban, median age, median peak methadone dose, median 
days retained, the percentage of BZD positive urine samples, and the one-year retention 
rate. For the purpose of this study, only a patient’s first treatment episode was considered. 
For the primary analysis, a Cox proportional hazard analysis was used to characterize the 
time to treatment discontinuation and the relative likelihood of treatment termination 
between the BZD positive and negative patient groups with adjustment for the impact of 
age, gender, northern and rural location. Cox proportional hazard analysis and log-rank 
test were performed using SPSS 24. Kaplan-Meier survival analysis was done using 
GraphPad Prism 7. 
Results: 
Patient Demographics 
 Our cohort consisted of 3,850 patients, 60% of which were male with a median 
age of 31.4 years old. 36% of patients resided in Northern Ontario and 16% lived in a 
rural setting. Those patients living in the North were 40.7% less likely to drop out of 
treatment by the one-year mark compared to patients in the South. Male patients were 
30.2% more likely to drop out of treatment than female patients. There were no 
significant differences in treatment retention for patients living in rural or urban centres. 
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Baseline BZD Use 
 Patients were stratified by baseline BZD use, which was defined by the presence 
of any BZD positive urine samples in the first month of treatment. Of the 3,850 patients, 
562 (15%) were considered baseline BZD users and 3,288 (85%) non-users. The ratio of 
female to male patients was greater in the BZD use group with 43.8% of BZD users 
being female, compared to only 39.9% of non-users being female. Female patients were 
34.5% more likely to be baseline BZD users than were males. Another difference in the 
two groups was in age, with the positive group having an increased median age of 34.3 
years compared to 30.8 years. Patients were 25.5% less likely to have a BZD positive 
urine sample in their first month of treatment if they lived in a rural area and were 23.6% 
less likely to have a BZD positive urine sample in their first month of treatment if they 
lived in the North. Baseline BZD users had an increased median peak dose of methadone 
(85 mg vs. 75 mg) and had a lower median retention of 215 days, compared to 265 days.  
Retention and Baseline BZD Use 
 The following variables were included in the Cox proportional hazard model: age 
[aHR= 0.98 (95% CI 0.975 – 0.984)], gender (female [aHR= 0.768 (95% CI 0.70 – 
0.84)]), geography (North [aHR= 0.59 (95% CI 0.538 – 0.655)] and rural [aHR= 0.982 
(95% CI 0.863 – 1.118)], and first-month BZD use [aHR= 1.149 (95% CI 1.022 – 
1.292)]. For those patients considered baseline BZD users, the one-year retention rate 
was 39.9%. For those patients who were BZD negative on admission, the one-year 
retention rate was 44%. Of the first month BZD users that remained at one year, 31.2% 
were BZD positive. Of the baseline non-users who remained at the one-year mark, 95% 
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were BZD negative. Importantly, patients were 14.9% more likely to drop out of 
treatment if they had BZD positive urine samples in their first month of treatment.  
Proportion of BZD Positive Urine Samples 
 In addition to being categorized by first-month BZD use, patients were also 
stratified by the proportion of BZD positive urine samples throughout treatment: 0-25%, 
25-50%, 50-75%, and 75-100%. Of the 3,850 patients, 3,556 had BZD positive urine 
samples less than 25% of the time. These patients experienced a one-year retention rate 
of 45%. 127 patients had BZD positive urine samples 25-50% of the time, with a 
retention rate of 32%. These patients were 26.6% more likely to not be retained, 
compared to those patients in the <25% group. 72 patients had BZD positive urine 
samples between 50-75% of the time, and they experienced a retention rate of 33%. 
These patients were 37.4% more likely to terminate treatment prematurely than the <25% 
group. Lastly, 97 patients had BZD positive urine samples more than 75% of the time, 
and they suffered the lowest retention rate of 14%. These patients were an alarmingly 
174.4% more likely to not be retained in treatment, compared to the <25% group.  
BZD Use and Geography 
 Patients were categorized as residing in Northern Ontario or Southern Ontario 
according to the Local Health Integration Network (LHIN) in which they lived; patients 
residing in LHIN 13 or 14 were considered Northern residents. For the proportion of 
BZD positive urine samples, patients in the North had retention rates of 56%, 33%, 17%, 
and 13%, respectively. Patients in the South experienced retention rates of 38%, 32%, 
36%, and 14%. In the Northern population, the greater the proportion of BZD positive 
urine samples, the lower the retention. However, in the Southern population, the decrease 
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is less pronounced. Instead, it appears that patients with >75% of urines BZD positive 
suffer the lowest retention rates.  
Discussion: 
Previous studies have revealed mixed findings about whether BZD use impacts 
OAT retention. A review of BZD use in OAT suggests that most studies have found that 
baseline BZD use is not predictive of decreased retention (Lintzeris et al. 2010). 
However, this is contrary to our findings. Our findings support the idea that baseline BZD 
use is predictive of treatment drop out, with these patients being 14.9% more likely to 
terminate treatment prematurely. Additionally, our results indicate that with increasing 
proportion of BZD positive urine samples, patients are at increased risk of premature 
dropout. Therefore, both BZD use at treatment outset and intensity of BZD use during 
OAT are correlated with decreased retention.  
Compared to previous studies on patients in OAT, the median age of our patient 
sample was younger, at 31 years (median age = 34.6 Brands et al. 2008; median age = 35 
Lavie et al. 2009; median age = 47 Chen et al. 2011). However the age distribution in our 
OAT treatment data set seems to reflect the opioid dependent population in Ontario at the 
time of the study. This is supported by a cross-sectional study of all opioid-related deaths 
in Ontario between 1991 and 2010, which found that most opioid-related deaths occurred 
among young adults aged 25-34 (Gomes et al. 2014). A study relying on self-reports of 
high schools students found that opioid use is increasing among adolescence (McCabe et 
al. 2012), therefore, it is possible that the opioid dependent population in Ontario has 
gotten younger in recent years, compared to the times and locations at which the other 
studies on BZD were conducted.  
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In terms of concurrent drug use, 15% of our patient population was BZD positive 
in their first month of treatment. Compared to previous studies, this number is low 
(Lintzeris et al., 2010). Our findings indicate that BZD use is more prevalent in the 
female population, which is supported by previous studies (Brands et al., 2008). The 
increased use of BZD in this population may be explained by the fact that females in 
OAT suffer from more psychiatric comorbidity than their male counterparts (Rowan-Szal 
et al., 2000; Peles et al., 2007). Studies have also found that female patients are more 
likely to receive a BZD prescription than are males (Bramness et al. 2007) and that the 
risks associated with BZD prescribing (ie. hospital visits, accidental injury) are increased 
in the female population (Schuman-Olivier et al. 2013). We also found a difference in the 
age of baseline users and non-users, with baseline users having a median age of 34.3 
years and non-users having a median age of 30.8 years. It may be the case that patients 
who have more severe mental health disorders (and therefore use BZD) take longer to 
come to treatment.   
Our results suggest that geography is an important factor to consider when 
studying BZD use. We found that patients living in rural areas and those patients living in 
the North were less likely to be baseline BZD users. When studying the impact of 
geography on retention, we confirmed the earlier finding that patients in the North were 
more likely to be retained in treatment, however we failed to confirm in this smaller 
sample size the correlation between rurality and retention (Eibl et al. 2015). The 
increased retention in the North may seem surprising, given that these patients face a 
variety of barriers when accessing health care. In remote Northern communities, patients 
often have to travel long distances to access OAT prescribing physicians and the 
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pharmacy that dispenses their methadone or buprenorphine (Eibl et al. 2015). It seems 
somewhat intuitive that given the added difficulties, these patients would experience 
decreased retention. However, this is not the case. In fact, patients in the North were 41% 
less likely to terminate treatment prematurely than were Southern patients. Given that 
Northern patients are less likely to be BZD users and BZD use is predictive of dropout, 
the increased retention may be partially explained by less BZD use in the North. 
However, given that this population was more likely to use cocaine and that cocaine use 
is predictive of treatment dropout, there are likely other reasons why this population 
benefits from greater retention. The enhanced treatment retention may be explained by 
Northern patients who overcome the barriers to treatment entry being more motivated to 
be successful in their treatment. The decreased BZD use in Northern and rural patients 
may be explained by inaccessibility in terms of availability or cost of non-prescribed 
BZD.  
Of the 3,288 patients who were considered baseline non-users, the vast majority 
(~95%) who were retained were also BZD negative at the one year mark. For the 
remaining 5%, it may be the case that patients received a BZD prescription during the 
course of their treatment. Of the 562 patients who were BZD positive in their first month 
of treatment, 49% of those that were retained were negative at 3 months, 59% at 6 
months, 61% at 9 months, and 69% at the one-year mark. Given that OAT does not treat 
BZD dependence, it may seem surprising that the majority of BZD users terminate BZD 
use during treatment. However, it may be the case that many of the initially positive 
patients were heavy BZD users and dropped out of treatment before reaching the 3rd, 9th, 
or 12th month. It may also be the result of contingency management, whereby a patient is 
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motivated to abstain from concurrent drug use in order to obtain carried (i.e. take home) 
doses. Contingency management might encourage a patient to decrease BZD use, given 
that it has been shown to reduce the use of other drugs in patients who are receiving OAT 
(Rawson et al. 2002). 
Although our patient sample had fewer BZD users than expected, it is important 
to consider why BZD use is so prevalent in OAT. One theory is that there is an increased 
prevalence of co-morbid mental health issues including depression, anxiety, and insomnia 
among patients enrolled in OAT (Carpentier et al., 2009; Mark et al., 2013). It is for this 
reason that patients are often prescribed BZD to treat their concurrent mental health 
disorders (Jones et al., 2012). A retrospective cohort study of over 2,000 patients 
receiving OAT found that 40% of patients had received at least one BZD prescription 
(Bramness et al., 2007). The current guidelines on how to manage patients with opioid 
dependence and co-occurring mental health disorders, for which BZD are clinically 
indicated, are unclear (CPSO 2011). Further research needs to inform physicians as to 
how they should manage these complex patients. However, not all BZD use is prescribed. 
A retrospective study of patients receiving methadone found that nearly 35% of patients 
who were BZD positive did not have an associated prescription (White et al. 2014).  
One of the main limitations of this study is the inability to detect whether a patient 
received a BZD prescription from a physician other than their OAT provider. The number 
of patients that received a BZD prescription from their OAT provider was known, 
however, this number was less than 7.2%. This is likely because the majority of BZD 
prescriptions are coming from physicians outside the OATC network. A retrospective 
cohort study that utilized a prescription database found that over 60% of BZD 
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prescriptions were written by a physician other than the OAT provider (Bramness et al. 
2007). Therefore, it is very likely that our detection of BZD prescriptions is insufficient. 
While this study captures the impact of general BZD use on OAT retention, it does not 
necessarily differentiate between clinical BZD use for mental health disorders, and non-
prescribed use. It is possible that a large proportion of our patient sample did have BZD 
prescriptions and were using BZD as clinically prescribed from a non-OAT physician. 
Another limitation is that we were unable to determine the dose of BZD taken by 
patients. Lastly, if a patient dropped out of treatment, we were not able to determine 
whether the patient simply terminated all OAT, began treatment at a non-OATC clinic, 
was incarcerated, hospitalized, or died.  
This study also has several strengths. While BZD use in OAT has been studied 
previously, it has not been studied in a regional context – in this case Northern vs. 
Southern Ontario. Of the studies that have been done, few have been longitudinal. Those 
studies that were longitudinal either had a much smaller sample size, relied on self-
reported data, or did not use a survival analysis to quantify the impact of BZD use and 
geography on treatment retention. Other strengths regarding study design include the 
large sample, the method of data collection, and the patient population. With nearly 4,000 
patients in our cohort, this study captures a substantial proportion of all patients receiving 
OAT in Ontario. Additionally, this study did not rely on patient self-report, as did many 
of the previous studies. Lastly, the fact that all patients in the cohort were from one 
network of clinics adds strength to the comparisons made between patients. 
The findings of this study suggest that BZD use is a marker for greater clinical 
complexity, and puts patients at increased risk of premature OAT discontinuation. Given 
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that treatment retention is correlated with better patient outcomes (Peles et al. 2008; 
Nosyk et al. 2010), it is important that physicians be cognizant of BZD detection in 
patients’ urine samples, as this could be a marker for decreased retention. Physicians 
should exercise caution when prescribing BZD to patients on OAT. However, further 
research needs to be done to better understand how prescribed BZD use and non-
prescribed use differentially impact treatment retention. 
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Table 2. Characteristics of baseline BZD users and non-users. Descriptive statistics were summarized for baseline characteristics 
of patients, and standardized differences were used to compare patient groups. Patients were considered baseline BZD users if they 
had any BZD positive urine samples in the first month of treatment.
 Initially Negative (n = 3288, 85.4%) Initially Positive (n = 562, 14.6%) 
Male / Female 1975 (60.1%) / 1313 (39.9%) 316 (56.2%) / 246 (43.8%) 
North / South 1239 (37.7%) / 2048 (62.3%) 166 (29.5%) / 396 (70.5%) 
Urban / Rural 2753 (83.8%) / 543 (16.2%) 499 (88.8%) / 63 (11.2%) 
Median Age (Q1, Q3; SD) 30.8 (25.3, 39.4; SD=10.2) 34.3 (28.1, 45.3; SD=10.9) 
Median Peak Methadone Dose (Q1, Q3; 
SD) 
75 (50, 100; SD=33) 85 (55, 115; SD=36) 
Median Peak Suboxone Dose ( Q1, Q3; 
SD) 
8 (8, 16; SD=7) 12 (8, 20; SD=8) 
Median Days Retained (Q1, Q3; SD) 265 (56, 526; SD=272) 215 (53, 519; SD=270) 
Median Percent Positive Results (Q1, Q3; 
SD) 
0.0 (0.0, 0.0; SD=4.9) 21.4 (6.8, 55.1; SD=32.1) 
Percent Positive 
Results 
[0, 25) 3252 (98.9%) 302 (53.7%) 
[25, 50) 31 (0.9%) 96 (17.1%) 
[50, 75) 4 (0.1%) 68 (12.1%) 
[75, 100] 1 (<0.1%) 96 (17.1%) 
At Month 3 
Day 60 to 90 
Positive / 
Negative 
144 (6.0%) / 2276 (94.0%) 204 (50.5%) / 200 (49.5%) 
Retained 2420 (73.6%) 404 (71.9%) 
At Month 6 
Day 150 to 180 
Positive / 
Negative 
109 (5.6%) / 1850 (94.4%) 128 (40.9%) / 185 (59.1%) 
Retained 1959 (59.6%) 313 (55.7%) 
At Month 9 
Day 240 to 270 
Positive / 
Negative 
88 (5.2%) / 1601 (94.8%) 104 (39.0%) / 163 (61.0%) 
Retained 1689 (51.4%) 267 (47.5%) 
At Month 12 
Day 330 to 360 
Positive / 
Negative 
80 (5.3%) / 1443 (94.7%) 74 (31.2%) / 163 (68.8%) 
Retained 1523 (46.3%) 237 (42.2%) 
Retained / Not-Retained 365 Days 1447 (44.0%) / 1841 (56.0%) 224 (39.9%) / 338 (60.1%) 
		 45	
Figure 2.1 - Treatment retention by baseline BZD use. A cox proportional hazard analysis was used to characterize the time to 
treatment discontinuation between the patient groups. Log-rank comparison of these curves yielded a Chi-Square value of 2.883 with a 
non-significant p value of 0.0895. Baseline BZD users were 14.9% more likely to drop out of treatment than baseline non-users 
























Figure 2.2 - Treatment retention by proportion of BZD positive urine samples. A cox proportional hazard analysis was used to 
characterize the time to treatment discontinuation across the four patient groups. Patients with 25-50% of urines BZD positive were 
26.6% more likely to drop out of treatment than patients in the 0-25% reference group [aHR=1.26 (95% CI 1.02 –1.57)]. Patients with 
50-75% of urines BZD positive were 37.4% more likely to drop out of treatment than patients in the 0-25% reference group 
[aHR=1.37(95% CI 1.03 –1.832)]. Patients with 75-100% of urines BZD positive were 174.4% more likely to drop out of treatment 
than patients in the 0-25% reference group [aHR=2.74(95% CI 2.19 –3.43)] 
 
 






















Figure 2.3 - Proportion of patients retained in treatment for one year, by frequency 
of BZD use, comparing North vs. South. The pattern of decreased retention with 
increased proportion of BZD positive urine samples is not seen in the Southern 
population, as it is in the Northern population. However, Southern patients with a high 
proportion of BZD positive urine samples (>75%) experienced decreased retention rates. 
Cross tabulations were performed and a signification association was found with the first 















Chapter 4: Conclusion 
 
Opioid Dependence 
 The prevalence of opioid dependence in Canada is on the rise (Green et al. 2011), 
which has serious implications for both opioid dependent individuals and society at large. 
The annual social cost of untreated opioid dependence in Canada is estimated to be over 
$45,000 dollars per user (Wall et al. 2000). This is in large part due to crime, law 
enforcement, utilization of health care services, and loss of productivity (Wall et al. 
2000). Along with an increase in the prevalence of opioid dependence, the rate of opioid 
prescribing in Ontario has risen substantially in recent years (Dhalla et al. 2009). With the 
addition of oxycodone to the Provincial drug formulary in 2000, oxycodone prescribing 
increased by 850% between 1991 and 2007 (Dhalla et al. 2009). This increase in opioid 
prescribing was associated with a 41% increase in opioid related death (Dhalla et al. 
2009), which rose 242% the following 20 years after 1991 (Gomes et al. 2014). 
Treatment Options 
Opioid agonist therapy (OAT) is the most effective form of treatment available to 
those patients who have developed opioid dependence. OAT is a substitution therapy 
whereby the patient is relieved of their opioid withdrawal, thereby eliminating the need to 
use opioids illicitly. Methadone and buprenorphine/naloxone (Suboxone) are the two 
most frequently used medications to treat opioid dependence in Canada. Methadone is a 
long acting opioid that is a full agonist, compared to buprenorphine, which is a partial 
agonist (CPSO 2011), Physicians require a special license to prescribe methadone (CPSO 
2011), which increases barriers for patients trying to access it. This is particularly true of 




2012). Suboxone has fewer prescribing limitations, but is not widely available in Canada 
due to restricted coverage in Provincial formularies, which changed significantly in 
Ontario in 2012. Other treatment options that are not available in Canada are slow-release 
morphine and intramuscular slow-release naltrexone, both of which have been shown to 
be effective in the treatment of opioid dependence (Winklbaur et al. 2008; Nunes et al. 
2015).  
OAT is a form of maintenance therapy, rather than a detoxification. Research has 
found that a maintenance-oriented approach to treating opioid dependence is more 
effective in reducing illicit opioid use and in retaining patients than is a detoxification 
approach (Woody et al. 2008). Studies have also found that gradual dose decreases mixed 
with dose stabilization is more effective in achieving long-term abstinence compared to 
tapering the methadone dose to zero (Nosyk et al. 2012). 
Benefits of OAT 
The benefits of OAT are widespread. OAT has been shown to reduce harm and 
allow patients to return to normal social, psychological, and physical functioning (Health 
Canada 2002). In addition to reducing illicit opioid use, OAT has also been shown to 
reduce concurrent drug use, including the use of cocaine and sedatives (Mattick et al. 
2014). OAT is also effective in reducing criminal activity, the risk of communicable 
disease, and mortality (Brands et al. 2002). Studies have found an immediate increase in 
the health-related quality of life in those patients who initiate OAT (Nosyk et al. 2015), 
as well as improved pregnancy outcomes for pregnant opioid-dependent women (Brands 
et al. 2002). However, the positive effects of OAT are maximized when patients are 




variety of positive health outcomes including reduced drug use, relapse, hospitalization, 
and mortality (Peles et al. 2008; Nosyk et al. 2010). In addition to providing a variety of 
health benefits, both methadone and buprenorphine are substantially less costly than no 
treatment at all (Connock et al. 2007). 
OAT in Ontario 
The availability of OAT has increased substantially in recent years with more than 
42,000 patients currently receiving OAT in Ontario (CPSO, 2015). Despite this, certain 
areas of the province – such as Northern rural communities – do not have access to these 
services (Kiepek et al. 2012). Northern Ontario has a chronic shortage of health care 
services (Strasser et al. 2008), a vast geographic landscape (Strasser et al. 2008), and a 
high prevalence of opioid use and opioid related death (Gomes et al. 2011) and many 
patients struggle to access this form of treatment. 
Despite the barriers that people living in Northern communities face, it was 
previously found that Northern Ontario patients experience better OAT retention than 
Southern patients (Eibl et al. 2015). The results of this thesis corroborate these findings, 
and may help explain why this pattern exists. It was previously postulated that the 
increased retention in the North may be due to less cocaine use. However, we found that 
cocaine use was more prevalent in the North than in the South. Therefore, the increased 
retention experienced by this group of patients is not because of less cocaine use. Instead, 
our findings strengthen the hypothesis that patients in the North who overcome the 
barriers in accessing OAT are more motivated to be successful in treatment. However, 
there does exist the possibility that the increased retention rates are due in part to less 




patients in the South. However the magnitude of the impact of lower BZD use is 
insufficient to fully explain the geographic differences in outcome. We found that 
patients residing in rural communities used less cocaine and less BZD than patients in 
urban settings. As mentioned previously, we found that Northern patients were more 
likely to use cocaine, but less likely to use BZD than their Southern counterparts. Further 
research needs to be done to understand whether this is a result of drug accessibility, or a 
result of BZD prescribing practices.  
Impact of Cocaine on OAT 
While OAT has been found to provide a variety of positive health benefits for 
patients, the course of treatment may be negatively impacted by concurrent drug use, 
such as the use of cocaine. Cocaine is a stimulant that causes dopamine accumulation at 
the brains synapse, leading to an increase in alertness (NIDA 2010). The existing 
literature on cocaine use in OAT is rather conclusive that cocaine use is correlated with 
decreased retention (DeMaria et al. 2000; Downey et al. 2000; Hartel et al. 1995; Magura 
et al. 2002; Brands et al. 2008; Salamina et al. 2010,;Sullivan et al. 2010, Proctor et al. 
2015). In this thesis, we found that this is true of both baseline and ongoing cocaine use. 
In addition to being at increased risk of drop-out, patients who use cocaine while 
receiving OAT have an increased risk profile for HIV (Grella et al. 1995), require 
increased doses of methadone (Maremanni et al. 2000), are more likely to use illicit 
opioids (Hartel et al. 1995), are more likely to suffer from psychological distress (Roux et 
al. 2016), and are at an increased risk of overdose (Visconti et al. 2015). Therefore, in 
addition to being correlated with decreased retention, the literature is conclusive that 




Impact of BZD on OAT 
Unlike with cocaine, the literature on BZD use and OAT retention is rather 
inconclusive. BZD are a class of psychoactive drugs that are non-opioid central nervous 
system depressants. BZD are typically used to treat anxiety, seizures, and acute alcohol 
withdrawal (Brands et al. 2000; Canadian Agency for Drugs and Technologies in Health, 
2014). BZD are clinically indicated for short-term use, and there exists little evidence to 
support its long-term use. Additionally, the use of BZD while in OAT puts patients at an 
increased risk of overdose and death, with as many as 32-50% of methadone or 
buprenorphine-related deaths involving BZD (Chan et al., 2006; Mikolaenko et al. 2002; 
Schifano et al., 2005; Shah et al., 2005). Studies have found that BZD use does not 
impact treatment retention (Kellogg et al., 2006; Peles et al. 2006; Brands et al. 2008), 
and others have found that it is predictive of premature drop-out (Schiff et al. 2007; Peles 
et al. 2010; Specka et al. 2011). Of note, members of our research group previously 
conducted a retrospective chart view of 172 patients receiving MMT in Toronto and 
found that ongoing BZD use was not correlated with decrease retention rates (Brands et 
al. 2008). However, this study was not able to differentiate between prescribed and non-
prescribed BZD use. Additionally, studies have found that baseline BZD use is correlated 
with lower retention rates, but that ongoing use is not (Eiroa-Orosa et al. 2010). This 
study includes a much larger sample size than previous studies on BZD use, determines 
BZD use through toxicology testing and clearly demonstrates that BZD use is correlated 
with decreased retention in OAT. 
Due to the conflicting literature, there currently exists a gap in knowledge with 




receiving OAT. More research needs to be done to better understand the role that 
concurrent BZD use plays on OAT outcomes, including whether prescribed vs. non-
prescribed BZD use differentially impacts treatment retention.  
Several studies have investigated the predictors of BZD use in OAT. Studies have 
found that being female (Brands et al., 2008), being Caucasian (Chen et al., 2011), having 
a history of psychiatric comorbidity (Brands et al., 2008, Chen et al., 2011), early onset 
of opioid use (Backmund et al., 2005), unemployment (Backmund et al., 2005, Bleich et 
al., 2002), having a previous history of imprisonment (Backmund et al., 2005, Bleich et 
al., 2002), and a history suicide attempts (Backmund et al., 2005) are associated with a 
greater likelihood of BZD use. Of note, an Isreali group found that males were more 
likely to be BZD abusers (Bleich et al., 2002). Additionally, a Norwegian study that 
examined BZD prescriptions found that females were more likely to be prescribed BZD 
than were males (Bramness et al., 2007). The results of this thesis found that female 
patients were 35% more likely to be BZD users than male patients and that BZD use was 
predictive of decreased retention. 
Impact of Treatment Program Characteristics  
While patient characteristics – such as concurrent drug use – may be of great 
importance in determining the outcome of OAT, treatment characteristics play an 
important role as well (Ball and Ross 1991). Certain OAT programs have been found to 
have much higher retention rates, which may be attributable to characteristics of the 
treatment program themselves, rather than patient characteristics (Ball and Ross 1991). In 
one retrospective study of patients receiving OAT at the Centre for Addiction and Mental 




(Brands et al. 2008). In this treatment program, patients received much more holistic care 
in treating their opioid dependence than is typically experienced and patients benefited 
from a two year retention rate of 60% (Brands et al. 2008). Therefore, the lower one-year 
retention rate of 43% may speak to the need for more holistic care in the OAT model. 
Particularly, patients who are deemed high risk of drop out (ie. BZD and cocaine using 
patients) may benefit from have programs with sufficient resources to address all of their 
treatment needs. 
Cannabis Use in the Opioid Dependent 
 While it is clear that concurrent drug use – in the form of cocaine and BZD use – 
may compromise the OAT clinical course, it may be the case that some concurrent drug 
actually correlates with more positive patient outcomes. Both Canada and the US have 
modified their laws with respect to medical cannabinoid use given its therapeutic role 
(Benyamina et al. 2014), and this appears to have had a positive effect on the opioid 
dependent population. A retrospective study of opioid overdose deaths from 1991 to 2010 
in the US found that the opioid overdose mortality rate per 100,000 population was 25% 
lower in those states with medical cannabis laws (Bachhuber et al. 2015). A separate 
study found that patients receiving opioid medication for chronic pain greatly benefit 
from medical cannabis use in terms of reduced opioid use. This retrospective cross-
sectional study found that patients using cannabis for chronic pain experienced 64% less 
opioid use, increased quality of life, and benefited from fewer side effects (Boehnke et al. 
2016). While this thesis did not study the role of cannabis in OAT, this is something that 






 The dataset used for this thesis was derived from anonymized electronic medical 
records from a network of 58 clinics across the Province, the OATC. This dataset 
includes patient demographics (age, gender, geographic location) as well as the results of 
patient urine toxicology results. Urine toxicology screening is typically done once or 
twice per week for all patients in this network of clinics. The results of urine toxicology 
screening dates back to 1999, with appointments dating back to 2004. 
Analysis 
 The time frame of this study was chosen as January 1st 2011 to June 17th, 2012, 
despite the fact that we had urine toxicology results dating back to 1999. The reason this 
study window was chosen was because of missing methadone dose dates in the year 
2010, therefore, patients would have been incorrectly captured as having terminated 
treatment, or potentially incorrectly captured as being a first-time patient. Only patients 
who were initiating first-time OAT were considered. Therefore, patients were excluded if 
they had previously initiated OAT in this clinic network (dating back to 1999). Patients 
were considered as being retained in treatment if they did not go a period of time of 30 
days without receiving a prescription for methadone or suboxone. This time period was 
chosen in order to capture a patient’s first treatment episode. The intention was to 
quantify a time from the day they initiate treatment to the day they leave treatment, while 
giving patients enough flexibility to miss an appointment or have a brief period of 







Both baseline and ongoing drug use was predictive of decreased retention. This 
was true of both cocaine and BZD. The higher the proportion of cocaine or BZD positive 
urine samples, the more likely patients are to terminate treatment prematurely. Similar to 
previous studies (Eibl et al. 2015), it was found that patients in the North are retained at a 
higher rate than patients in the South. Patients in Northern Ontario were less likely to use 
BZD, but more likely to use cocaine than patients in the South. Patients in rural 
communities were less likely to use cocaine and BZD than were their urban counterparts. 
With respect to both cocaine and BZD, concurrent drug use decreased with treatment 
duration. For the most part, these findings are in agreement with the existing literature. 
Limitations 
One of the main considerations that requires more study is the difference in 
prescribed and non-prescribed BZD use, which was not done in this thesis. To better 
understand the impact of clinical BZD use on OAT retention, further research must be 
done using prescription data, such as data from the Institute for Clinical and Evaluative 
Sciences (ICES). Linking datasets from ICES with the OATC urine toxicology screening 
could allow for the identification of those patients who have received a BZD prescription 
and are using BZD as clinically indicated, and compare their retention to patients using 
non-prescribed BZD (those without a prescription but who have BZD positive urine 
screens). Differentiating between the two would better inform physicians as to how to 
manage patients who are in OAT and are also clinically indicated for BZD. This would 
also potentially allow us to study drug diversion by identifying those patients who fill a 




Other limitations of this thesis include a potential for selection bias, potential lack 
of external validity, the inability to determine certain patient details, and the limitations 
surrounding the type of urine toxicology screening used. The potential for selection bias 
lies in the fact that only one network of clinics offering OAT was studied. This is the 
largest network of OAT providing clinics in the province and consists of a substantial 
number of patients receiving OAT in Ontario, however, the results of this thesis may not 
be generalizable to all patients receiving OAT in Ontario, Canada, or worldwide. Due to 
the retrospective nature of our research, we were unable to determine certain patient 
details that were not included in the dataset. Details such as years of drug use, or the 
amount of drug taken remain unknown. Additionally, if a patient terminated treatment we 
were unable to determine whether they terminated all OAT, switched to a different 
network of clinics, had an extended hospital stay or incarceration, or died. If it was the 
case that a patient died, this would be considered a negative outcome and this patient 
would be captured in our definition of not retained. However, if a patient transitioned to a 
non-OATC clinic, this would be a positive outcome that would also be captured in our 
definition of not retained, which in this case, would be a misidentified negative outcome. 
Lastly, the urine toxicology screening used is an immunoassay that does not use 
confirmatory quantitative testing such as gas chromatography or mass spectrometry. 
Therefore, there is the potential for false positive or false negative results. However the 
products used during the time of this study were approved by Health Canada and meet 
high clinical standards for sensitivity and specificity. 
Importantly, the framework used in this research (the transtheoretical model) has 




transtheoretical model does not utilize a continuum, but rather distinct categories: pre-
contemplation, contemplation, preparation, action, or maintenance. Therefore, patients 
can only be classified as being in one of five discrete stages, which may not accurately 
describe each individual patient. Additionally, because of the retrospective nature of our 
research, we aren’t able to determine where patients were likely to be categorized within 
the stages of change. Secondly, the time frames that characterize each category are 
arbitrary and inflexible. For example, if a patient intends on modifying their health 
behaviour within the next three weeks, they are considered to be in the preparation stage. 
However, if they plan on modifying their health behaviour within the next five weeks, 
they remain in the contemplation category. Thirdly, there is no objective focus on the 
patient’s actual preparedness for change with this model. Instead, the categorization relies 
entirely on the patient’s self-reported intention to quit. While this is certainly important to 
consider, their intention to change their health behaviour may be unrealistic or unreliable. 
Lastly, this model does not consider the uniqueness of certain populations (age, gender, 
race, geographic residence) and therefore may not apply to all demographics equally. 
Implications for Further Research 
The findings from our research have implications to inform clinical guidelines 
and physician practice. It is clear from our findings that baseline BZD and cocaine use 
are markers for premature drop-out, and that the higher the incidence of concurrent drug 
use, the more likely patients are to drop-out. Physicians should be aware of BZD and 
cocaine detection in urine toxicology screening, and these patients should be closely 
monitored throughout treatment. With further research regarding prescribed BZD use and 




patients in OAT. As it stands, physicians should be cautious when prescribing BZD to 
these patients, as this may put patients at increased risk of premature drop-out, overdose, 
and death. For patients with cocaine use, particularly when it is high intensity and 
sustained, the risk of premature dropout is markedly higher and physicians should 
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